Technological Outcomes
기술 성과
| Category | Project | Country of entry | |
|---|---|---|---|
|
Hybrozyme™ Technology |
ALT-B4 | Composition of matter |
|
|
Pharmaceutical Composition I |
|
||
|
Pharmaceutical Composition II |
|
||
| Variants I |
|
||
| Variants II |
|
||
| Method |
|
||
| Hyaluronidase | Mammalian PH20 |
|
|
| Hyal1 variants |
|
||
| Long Acting Platform | NexPTM Technology I |
|
|
| NexPTM Technology II |
|
||
| ALT-P1 |
|
||
|
|
|||
| ALT-S4 |
|
||
| ALT-B4 | Formulation |
|
|
| Method |
|
||
| ALT-Q2 |
|
||
| ALT-M4 |
|
||
|
NexMab™ADC Technology |
Core Technology |
|
|
| ALT-P7 | Method |
|
|
| Formulation |
|
||
| ALT-Q5 | ADC |
|
|
| Ab |
|
||
|
Biosimilar Development |
ALT-L1 |
|
|
| ALT-L6 |
|
||
| ALT-L9 | Fomulation |
|
|
| Method |
|
||
| Purification |
|
||
| High dose |
|
||
| PFS |
|
||
(2025.11.12. 기준)